(Q37727235)

22 August 2017

1 reference

title

Emerging drugs for the management of cancer treatment induced bone loss (English)

1 reference

22 August 2017

Francesco Bertoldo

1

1 reference

22 August 2017

Serena Pancheri

series ordinal

2

1 reference

22 August 2017

Sonia Zenari

series ordinal

3

1 reference

22 August 2017

Stefania Boldini

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

323-342

1 reference

Osteoporosis due to cancer treatment: pathogenesis and management

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Osteoporosis in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Therapy Insight: osteoporosis during hormone therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Skeletal complications of breast cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

A high incidence of vertebral fracture in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Aromatase inhibitors: rationale and use in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Sex steroids and the construction and conservation of the adult skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Changes in bone mineral density with age in men and women: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Cancer treatment-induced bone loss in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer--a prospective, controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Fracture risk in Danish men with prostate cancer: a nationwide register study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone health in men receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone quality--the material and structural basis of bone strength and fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Practical guidance for the management of aromatase inhibitor-associated bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

New approaches in the treatment of Adamantiades-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Strontium ranelate improves bone microarchitecture in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone turnover mediates preferential localization of prostate cancer in the skeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Global vitamin D status and determinants of hypovitaminosis D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Vitamin D status and response to treatment in post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Non-compliance: the Achilles' heel of anti-fracture efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Fracture outcomes related to persistence and compliance with oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Denosumab in osteoporosis and oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Future therapeutic targets in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bisphosphonates: from the laboratory to the clinic and back again

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

BMP signaling in skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728211003631385

10.1517/14728211003631385

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference